CCTV net news: the new year, see a doctor medication also have good news. The Office of Centralized Drug Purchase and Use of the State Organization has issued a national centralized drug purchase document,33 varieties have been selected as the second batch of national centralized drug purchase list, and another wave of reduced prices of drugs is on the way.
The second batch of national drug centralized purchase list covers hypertension, diabetes and other major chronic diseases, as well as anti-tumor and rare disease drugs. According to the purchase catalogue, acarbose and other oral hypoglycemic drugs; omesartan ester and other hypertension drugs; treatment of rare diseases of pulmonary arterial hypertension drugs anlishengtan tablets, as well as anti-cancer drugs tegio, abitron and other drugs shortlisted.
According to the centralized procurement work arrangement, the bid opening will produce the result of the proposed selection on January 17,2020, and patients from all over the country will use the second batch of concentrated belt quantity to purchase the selected drugs in April this year.
Some of the self-financed varieties that are not included in the health care catalogue are also joining the centralized purchase this time. Industry insiders point out that this means that self-financed drugs will also feel the pressure to reduce prices brought by concentrated purchases.
It has become a trend to guide drug price reduction with the mode of purchasing with quantity. Recently, more than 50,000 small and medium-sized pharmacies in the country formed an alliance, through the national retail drugstore sales and pharmaceutical companies to negotiate to achieve volume for price, reduce drug prices. Let the common people take cheap rest assured medicine, let drugstores get both scale and profit growth, fully promote the implementation of pharmaceutical separation process.